Skip to main content

Table 2 Incidence of adverse events with onset from start of run-in medication to 4 weeks after randomization (all patients)

From: Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial

Preferred term No. % 95% confidence intervals
Total number of patients 41 100%;  
Patients with at least one AE 37 90% (77–97%)
Headache 11 27% (14–43%)
Nasopharyngitis 11 27% (14–43%)
Cough 8 20% (9–35%)
Nausea 8 20% (9–35%)
Febrile infection 6 15% (6–29%)
Diarrhoea 5 12% (4–26%)
Dizziness 4 10% (3–23%)
Fall 3 7% (2–20%)
Fatigue 3 7% (2–20%)
Pyrexia 3 7% (2–20%)
Abdominal pain 2 5% (0.6–17%)
Back pain 2 5% (0.6–17%)
Chest pain 2 5% (0.6–17%)
Decreased appetite 2 5% (0.6–17%)
Muscular weakness 2 5% (0.6–17%)
Rash 2 5% (0.6–17%)
  1. Data are number of patients, percentage; 95% confidence interval